Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.32 |
| ▸ | FABP7 | O15540 | 2/20 | 0.32 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.32 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.31 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | RAB9A | P51151 | 2/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | TP53 | P04637 | 2/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
| ▸ | TOP2A | P11388 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14062500 | 0.86 | CA1 (0.42) | CA1CA2HTR2AKMT2AFABP5 | |
| SCHEMBL12402581 | 0.74 | HTR2A (0.47) | CA1CA2HTR2AKMT2ANR3C1 | |
| SCHEMBL13826222 | 0.73 | KMT2A (0.48) | CA1CA2KMT2AFABP5FABP7 | |
| SCHEMBL14627541 | 0.72 | KMT2A (0.42) | KMT2AALDH1A1SMN1; SMN2TSHRTDP1 | |
| SCHEMBL13258633 | 0.71 | FABP5 (0.51) | CA1CA2HTR2AKMT2AFABP5 | |
| SCHEMBL29844647 | 0.70 | HTR2A (0.47) | CA1CA2HTR2AKMT2AFABP5 | |
| SCHEMBL1230997 | 0.70 | HTR2A (0.47) | CA1CA2HTR2AKMT2AFABP5 | |
| SCHEMBL28936568 | 0.69 | KMT2A (0.41) | CA1CA2KMT2AFABP5FABP7 | |
| SCHEMBL3919560 | 0.68 | CYP1A2 (0.43) | TOP2ADUT | |
| SCHEMBL28342668 | 0.68 | TDO2 (0.48) | CA1CA2HTR2AKMT2ACDK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2170821-B1 | METHOD FOR PREPARING FMOC-BASED HYDROLYSABLE LINKERS | Baxalta GmbH (CH) | 2016-11-30 | — | — | EP | disclosed |
| US-8871949-B2 | Method for preparing FMOC-based hydrolysable linkers | BAXTER INTERNATIONAL INC. (US) | 2014-10-28 | — | — | US | disclosed |
| US-8871949-B2 | Method for preparing FMOC-based hydrolysable linkers | BAXTER INTERNATIONAL INC. (US) | 2014-10-28 | — | — | US | disclosed |
| US-8871949-B2 | Method for preparing FMOC-based hydrolysable linkers | BAXTER INTERNATIONAL INC. (US) | 2014-10-28 | — | — | US | disclosed |
| EP-1628998-B1 | A TAG FOR PURIFICATION OF PEPTIDES | ALMAC SCIENCES SCOTLAND LTD (GB) | 2011-02-23 | — | — | EP | disclosed |
| US-20100197940-A1 | Method for Preparing FMOC-Based Hydrolysable Linkers | BAXTER INTERNATIONAL INC. (US) | 2010-08-05 | — | — | US | disclosed |
| US-20100197940-A1 | Method for Preparing FMOC-Based Hydrolysable Linkers | BAXTER INTERNATIONAL INC. (US) | 2010-08-05 | — | — | US | disclosed |
| US-7714147-B2 | reacting a 9-hydroxymethyl-2-amino fluorene with a silyl protecting reagent e.g. tert-butyldimethylsilyl chloride to form tert-butyldimethylsiloxy-9-methyl-2-aminofluorene, reacting intermediate with 3-maleimidopropionic acid; protecting; chemical intermediates for protein and peptide drugs | BAXTER INTERNATIONAL INC. (US) | 2010-05-11 | — | — | US | disclosed |
| US-7714147-B2 | reacting a 9-hydroxymethyl-2-amino fluorene with a silyl protecting reagent e.g. tert-butyldimethylsilyl chloride to form tert-butyldimethylsiloxy-9-methyl-2-aminofluorene, reacting intermediate with 3-maleimidopropionic acid; protecting; chemical intermediates for protein and peptide drugs | BAXTER INTERNATIONAL INC. (US) | 2010-05-11 | — | — | US | disclosed |
| EP-2170821-A1 | METHOD FOR PREPARING FMOC-BASED HYDROLYSABLE LINKERS | BAXTER INTERNATIONAL INC. (US) | 2010-04-07 | — | — | EP | disclosed |
| US-20090005574-A1 | reacting a 9-hydroxymethyl-2-amino fluorene with a silyl protecting reagent e.g. tert-butyldimethylsilyl chloride to form tert-butyldimethylsiloxy-9-methyl-2-aminofluorene, reacting intermediate with 3-maleimidopropionic acid; protecting; chemical intermediates for protein and peptide drugs | BAXTER INTERNATIONAL INC. (US) | 2009-01-01 | — | — | US | disclosed |
| US-20090005574-A1 | reacting a 9-hydroxymethyl-2-amino fluorene with a silyl protecting reagent e.g. tert-butyldimethylsilyl chloride to form tert-butyldimethylsiloxy-9-methyl-2-aminofluorene, reacting intermediate with 3-maleimidopropionic acid; protecting; chemical intermediates for protein and peptide drugs | BAXTER INTERNATIONAL INC. (US) | 2009-01-01 | — | — | US | disclosed |
| WO-2009000523-A1 | METHOD FOR PREPARING FMOC-BASED HYDROLYSABLE LINKERS | BAXTER INTERNATIONAL INC. (US) | 2008-12-31 | — | — | WO | disclosed |
| US-20070010673-A1 | Purification means | CSS-ALBACHEM LIMITED (GB) | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197940-A1 | Method for Preparing FMOC-Based Hydrolysable Linkers | DNPEP, VIP, HM13 | CA1 714/4885CA2 3866/4885HTR2A 3213/4885 |
| US-20090005574-A1 | reacting a 9-hydroxymethyl-2-amino fluorene with a silyl protecting reagent e.g. tert-butyldimethylsilyl chloride to form tert-butyldimethylsiloxy-9-methyl-2-aminofluorene, reacting intermediate with 3-maleimidopropionic acid; protecting; chemical intermediates for protein and peptide drugs | HGFAC, PTMS, PRMT9 | CA1 1896/4885CA2 2461/4885HTR2A 2114/4885 |
| US-20070010673-A1 | Purification means | ANPEP, DNPEP, VIP | CA1 2145/4885CA2 4170/4885HTR2A 4464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.